<b><i>In vitro</i> CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic</b>.

Säll, Carolina; Alifrangis, Lene; Dahl, Kirsten; Friedrichsen, Martin Haljeta; Nygård, Sune Boris; Kristensen, Kim

In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic.

Säll, Carolina; Alifrangis, Lene; Dahl, Kirsten; Friedrichsen, Martin Haljeta; Nygård, Sune Boris; Kristensen, Kim.

Afiliación

Säll C; Novo Nordisk A/S, Denmark cxls@novonordisk.com.
Alifrangis L; Novo Nordisk A/S, Denmark.
Dahl K; Novo Nordisk A/S, Denmark.
Friedrichsen MH; Novo Nordisk A/S, Denmark.
Nygård SB; Novo Nordisk A/S, Denmark.
Kristensen K; Novo Nordisk A/S, Denmark.

Drug Metab Dispos ; 2022 Jun 09.

Article en En | MEDLINE | ID: mdl-35680133

Palabras clave

Drug development; Peptide hormones; clinical pharmacology; cytochrome P450 regulation; drug-drug interactions; hepatocytes; in vitro-in vivo prediction (IVIVE); physiologically-based pharmacokinetic modeling/PBPK

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google